Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zimberelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zimberelimab (Sepalizumab) is a human monoclonal antibody that belongs to a class of immuno-oncology agents. It is formulated as injectable solution for intravenous drip route of administration. Zimberelimab is indicated for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).
GLS-010 (AB-122) is under development for the treatment of metastatic cervical cancer, metastatic castrate resistant prostate cancer (mCRPC), locally advanced/metastatic pancreatic cancer, glioblastoma multiforme (GBM), recurrent glioblastoma multiforme (GBM), rectal cancer, gastric cancer, esophageal cancer, non-small-cell lung cancer, squamous cell carcinoma of the head and neck, renal cell carcinoma, urothelial cancer, breast cancer, colorectal cancer (CRC), prostate cancer, melanoma, pancreatic ductal adenocarcinoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or gastroesophageal cancer, liver cancer, nasopharyngeal cancer, peripheral T lymphoma, natural killer cell lymphoma, bile duct cancer, metastatic melanoma, cervical cancer, gastric cancer, esophageal cancer, multiple myeloma (kahler disease), non-hodgkin lymphoma, diffuse large B-cell lymphoma, adenocarcinoma of the gastroesophageal junction, pancreatic ductal adenocarcinoma, hepatocellular cancer, bile duct cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gall bladder cancer and colorectal cancer. The drug candidate is a humanized monoclonal antibody. It is administered as an intravenous infusion. GLS-010 acts by targeting PD-1. It is developed based on OmniRat technology platform.
Arcus Biosciences overview
Arcus Biosciences operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. The company has in-house specialization in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. Arcus Biosciences is headquartered in Hayward, California, the US.
For a complete picture of Zimberelimab’s drug-specific PTSR and LoA scores, buy the report here.